TABLE 1.
Patient characteristics in the cohort.
| Characteristics | Overall (n = 308) | PCT alone (n = 69) | PCT + LRRT (n = 105) | PCT + LRRT + bRT (n = 134) | p |
|---|---|---|---|---|---|
| Age (years) | |||||
| ≤ 45 | 145 (47.08) | 30 (43.48) | 49 (46.67) | 66 (49.25) | 0.733 |
| > 45 | 163 (52.92) | 39 (56.52) | 56 (53.33) | 68 (50.75) | |
| Sex | |||||
| Male | 251 (81.49) | 58 (84.06) | 92 (87.62) | 101 (75.37) | 0.044 |
| Female | 57 (18.51) | 11 (15.94) | 13 (12.38) | 33 (24.63) | |
| T stage | |||||
| 1–2 | 49 (15.91) | 8 (11.59) | 20 (19.05) | 21 (15.67) | 0.419 |
| 3–4 | 259 (84.09) | 61 (88.41) | 85 (80.95) | 113 (84.33) | |
| N stage | |||||
| 0–1 | 56 (18.18) | 15 (21.74) | 20 (19.05) | 21 (15.67) | 0.547 |
| 2–3 | 252 (81.82) | 54 (78.26) | 85 (80.95) | 113 (84.33) | |
| EBV DNA (copies/mL) | |||||
| < 10,000 | 148 (48.05) | 31 (44.93) | 44 (41.90) | 73 (54.48) | 0.130 |
| ≥ 10,000 | 160 (51.95) | 38 (55.07) | 61 (58.10) | 61 (45.52) | |
| ALP (U/L) | |||||
| < 110 | 278 (90.26) | 62 (89.86) | 93 (88.57) | 123 (91.79) | 0.701 |
| ≥ 110 | 30 (9.74) | 7 (10.14) | 12 (11.43) | 11 (8.21) | |
| LDH (U/L) | |||||
| < 250 | 262 (85.06) | 52 (75.36) | 90 (85.71) | 120 (89.55) | 0.026 |
| ≥ 250 | 46 (14.94) | 17 (24.64) | 15 (14.29) | 14 (10.45) | |
| No. of metastatic lesions | |||||
| 1–3 | 267 (86.69) | 56 (81.16) | 82 (78.10) | 129 (96.27) | 0.001 |
| 4–5 | 41 (13.31) | 13 (18.84) | 23 (21.90) | 5 (3.73) | |
|
Property | |||||
| Osteogenesis | 197 (63.96) | 37 (53.62) | 66 (62.86) | 94 (70.15) | 0.065 |
| Osteolysis | 111 (36.04) | 32 (46.38) | 39 (37.14) | 40 (29.85) | |
| PCT regimen | |||||
| TPF | 93 (30.19) | 9 (13.04) | 32 (30.48) | 52 (38.81) | 0.001 |
| TP | 76 (24.68) | 15 (21.74) | 23 (21.90) | 38 (28.36) | |
| PF | 90 (29.22) | 27 (39.13) | 34 (32.38) | 29 (21.64) | |
| GP | 24 (7.79) | 11 (15.94) | 6 (5.71) | 7 (5.22) | |
| Multiple or other regimes | 25 (8.12) | 7 (10.14) | 10 (9.52) | 8 (5.97) | |
| Response after PCT | |||||
| PR | 224 (72.73) | 48 (69.57) | 78 (74.29) | 98 (73.13) | 0.784 |
| PD/SD | 84 (27.27) | 21 (30.43) | 27 (25.71) | 36 (26.87) | |
| Administration of CCT | |||||
| Yes | 125 (40.58) | 0 (0.00) | 52 (49.52) | 73 (54.48) | < 0.001 |
| No | 183 (59.42) | 69 (100.00) | 53 (50.48) | 61 (45.52) | |
| Any bone symptoms | |||||
| Yes | 14 (4.54) | 5 (7.25) | 2 (1.90) | 7 (5.22) | 0.224 |
| No | 294 (95.46) | 64 (92.75) | 103 (98.10) | 127 (94.78) | |
| Immunotherapy | |||||
| Yes | 12 (3.90) | 5 (7.25) | 2 (1.90) | 5 (3.73) | 0.203 |
| No | 296 (96.10) | 64 (92.75) | 103 (98.10) | 129 (96.27) | |
Abbreviations: ALP, alkaline phosphatase; bRT, radiotherapy to metastatic bone; CCT, concurrent chemotherapy; CR, complete response; EBV, Epstein–Barr virus; GP, gemcitabine plus cisplatin; LDH, lactic dehydrogenase; LRRT, locoregional radiotherapy; PCT, palliative chemotherapy; PD progression disease; PF, cisplatin plus 5‐fluorouracil; PR, partial response; RT, radiotherapy; SD, stable disease; TP, paclitaxel plus cisplatin; TPF, paclitaxel plus cisplatin and 5‐fluorouracil.